California Weighs $8.4 Billion Immunology Bond
Proposition 38 would fund immunology research and therapies through state-authorized bonds, with a 10% revenue requirement intended to repay the state.
Updated on Nov. 3, 2026 in Biotech
Live Poll
Should California borrow $8.4 billion in bonds to fund immunology research?
California voters are weighing Proposition 38, which would authorize the state to sell $8.4 billion in bonds to finance immunology research and therapies. The measure comes as the Trump administration has cut billions of dollars in federal funding for medical research at universities and medical centers.
Why it matters
Supporters say the measure would support research into diseases such as cancer, heart disease and Alzheimer's at a time of reduced federal research funding. Opponents question how the funds would be allocated, given criteria that critics say leave only one qualified institution.
The measure authorizes $8.4 billion in state bonds and requires 10% of revenue from funded research to be returned to the state, with revenue going first to the General Fund until the bond and interest are repaid. Repayment could take decades, and critics note the eligibility criteria may leave only one qualifying institution.
The players
Gary Michelson
A retired surgeon and billionaire inventor of medical devices who has donated over $40 million to the Yes on Prop. 38 campaign.
Robert Kaplan
A senior scholar at the Stanford University School of Medicine who serves as co-chair of the No on Prop 38 campaign.
The details
Proposition 38 would split the bond funds evenly between a single University of California-affiliated nonprofit medical research institute and research grants. Gary Michelson, a retired surgeon and billionaire inventor of medical devices, has donated more than $40 million to the Yes campaign, while Robert Kaplan of Stanford University co-chairs the No campaign.
Timeline
November 3, 2026: California voters decide on Proposition 38.
Big Picture
Proposition 38 is a state-level response to the Trump administration's cuts to federal medical research funding at universities and medical centers. It proposes to replace some of that lost support through bonds rather than through federal appropriations.
If approved, Proposition 38 would direct $8.4 billion in state bond funds toward immunology research and therapies, with 10% of resulting revenue returned to the state. Readers in California would see the measure's effects through state spending and any therapies or research jobs that follow.
The takeaway
Proposition 38 pairs a large state investment in immunology with a revenue-return mechanism, so its long-term cost and benefit depend on how quickly funded research generates repayable revenue. Voters will weigh that tradeoff alongside questions about how eligibility criteria are applied.
What happens next
Voters decide on Proposition 38 on November 3, 2026.
Further reading
Explore more California Biotech coverage for context on state-funded research efforts.
Live Poll
Should California borrow $8.4 billion in bonds to fund immunology research?
